CVS Caremark® Value Formulary Effective as of 07/01/2021 Value Formulary 07/01/2021 INTRODUCTION....................................................................................................................................................................................................... 4 PREFACE ................................................................................................................................................................................................................. 4 PHARMACY AND THERAPEUTICS (P&T) COMMITTEE ...................................................................................................................................... 4 DRUG LIST PRODUCT DESCRIPTIONS ................................................................................................................................................................ 4 GENERIC SUBSTITUTION ...................................................................................................................................................................................... 5 SPECIALTY MEDICATIONS .................................................................................................................................................................................... 6 PLAN DESIGN.......................................................................................................................................................................................................... 6 PREVENTIVE SERVICES ........................................................................................................................................................................................ 7 LEGEND ................................................................................................................................................................................................................... 7 NOTICE ..................................................................................................................................................................................................................... 8 ANALGESICS........................................................................................................................................................................................................... 9 ANALGESICS, OTHER .................................................................................................................................................................................. 9 NSAIDs ........................................................................................................................................................................................................... 9 GOUT ............................................................................................................................................................................................................. 9 OPIOID ANALGESICS ................................................................................................................................................................................... 9 VISCOSUPPLEMENTS ............................................................................................................................................................................... 10 ANTI-INFECTIVES ................................................................................................................................................................................................. 10 ANTIBACTERIALS ....................................................................................................................................................................................... 11 ANTIFUNGALS ............................................................................................................................................................................................ 11 ANTIRETROVIRAL AGENTS ...................................................................................................................................................................... 12 ANTITUBERCULAR AGENTS ..................................................................................................................................................................... 13 ANTIVIRALS................................................................................................................................................................................................. 13 MISCELLANEOUS ....................................................................................................................................................................................... 13 ANTINEOPLASTIC AGENTS ................................................................................................................................................................................ 14 ALKYLATING AGENTS ............................................................................................................................................................................... 14 ANTIMETABOLITES .................................................................................................................................................................................... 14 BIOSIMILARS............................................................................................................................................................................................... 14 HORMONAL ANTINEOPLASTIC AGENTS ................................................................................................................................................. 14 KINASE INHIBITORS ................................................................................................................................................................................... 15 MULTIPLE MYELOMA ................................................................................................................................................................................. 15 PROSTATE CANCER .................................................................................................................................................................................. 15 MISCELLANEOUS ....................................................................................................................................................................................... 16 CARDIOVASCULAR .............................................................................................................................................................................................. 16 ACE INHIBITORS......................................................................................................................................................................................... 16 ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS ........................................................................................................ 16 ACE INHIBITOR/DIURETIC COMBINATIONS ............................................................................................................................................ 16 ADRENOLYTICS, CENTRAL ....................................................................................................................................................................... 17 ALDOSTERONE RECEPTOR ANTAGONISTS .......................................................................................................................................... 17 ANGIOTENSIN II RECEPTOR ANTAGONISTS/DIURETIC COMBINATIONS ........................................................................................... 17 ANGIOTENSIN II RECEPTOR ANTAGONIST/CALCIUM CHANNEL BLOCKER COMBINATIONS ......................................................... 17 ANTIARRHYTHMICS ................................................................................................................................................................................... 17 ANTILIPEMICS............................................................................................................................................................................................. 17 BETA-BLOCKERS ....................................................................................................................................................................................... 18 BETA-BLOCKER/DIURETIC COMBINATIONS ........................................................................................................................................... 18 CALCIUM CHANNEL BLOCKERS .............................................................................................................................................................. 18 DIGITALIS GLYCOSIDES ............................................................................................................................................................................ 19 DIURETICS .................................................................................................................................................................................................. 19 HEART FAILURE ......................................................................................................................................................................................... 19 NITRATES ...................................................................................................................................................................................................